Comparison of once-daily fosamprenavir boosted with either 100 or 200mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758

AIDS Research and Human Retroviruses

Volumn 25, Issue 4, 2009, Pages 395-403

  Hicks, Charles B ^a   Dejesus, Edwin ^b   Sloan, Louis M ^b   Sension, Michael G ^c   Wohl, David A ^d   Liao, Qiming ^e   Ross, Lisa L ^e   Pakes, Gary E ^e   Pappa, Keith A ^e   Lancaster, C Tracey ^e  

^a DUKE UNIVERSITY   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Texas ID Consultants   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 64849117166     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0231     Document Type: Article

References (19)

1. Gathe JC Jr, Ive P, Wood R, et al.: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-1537.
2. Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomized non-inferiority trial. Lancet 2006;368:476-482.
3. DeJesus E, Lamarca A, Sension M, et al.: The CONTEXT study: Efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure - 24-week results. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 10-14, 2003. Abstract/ presentation 178.
4. Cooper CL, van Heeswijk RPG, Gallicano K, and Cameron DW: A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-1592.
5. Ruane PJ, Luber AD, Wire MB, et al.: Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 2007;51: 560-565.
6. Smith KY, Weinberg WG, DeJesus E, et al.: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008; 5(5):1-10.
7. Hsu R, Walker-Reed K, and Acosta E: Fosamprenavir (FPV) with low-dose ritonavir (RTV) once-daily (QD) in HIV-infected subjects. Presented at the 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, April 20-22, 2006. Abstract/poster 71.
8. + patients and in antiretroviral-experienced patients switched to FPV/r due to intolerance to prior regimens: BOLD100 (COL109766). Presentedatthe American Collegeof Clinical Pharmacy 2007 Annual Meeting, Denver, Colorado, October 14-17, 2007. Poster 110E.
9. DeWit S, Poll B, Necsoi C, and Clumeck N: Fosamprenavir boosted with a single 100mg capsule of ritonavir as part of a once daily first line regimen in näive patients. Presented at the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16, 2006. Poster P17.
10. Muret P, Muret P, Montange D, et al.: Assessment of am-prenavir plasma Cmin levels in patients receiving once-daily fosamprenavir in combination with either 100 or 200mg ritonavir. Presented at the Congrès P2T Physiology, Pharmacology and Thérapeutics, Toulouse, France, April 2007. Abstract 216.
11. National Institute of Allergy and Infectious Diseases (NIAID): Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0. Division of Acquired Immunodeficiency Syndrome (DAIDS), Washington, DC, 2004.
12. Wohl D, DeJesus E, Sloan L, et al.: Limb and trunk fat changes by total body DEXA alter 96 weeks of treatment with once-daily (QD) fosamprenavir (FPV) boosted with either 100mg or 200mg of ritonavir (/r) plus abacavir (ABC)/lamivudine (3TC): COL100758. Presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 25-28, 2008. Abstract.
13. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125.
14. Levey AS, Bosch JP, Lewis JB, et al., for the Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470.
15. MacManus, Yates PJ, Elston RC, et al.: GW433908/ritonavir once daily in antiretroviral therapy-naïve HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS 2004; 18:651-655.
16. MacManus S, Yates PJ, White S, Richards N, and Snowden W: GW433908 in ART-naïve subjects: Absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract/poster 598.
17. Sale M, Sadler BM, and Stein DS: Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002;46:746-754.
18. Wood R, Arasteh K, Stellbring H-J, et al.: Six-week randomized controlled trial to compare the tolerabilities, pharmaco-kinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004;48:116-123.
19. + patients stabilized on fosamprenavir (FPV) 1400mg+FTC/TDF 200/ 300mg QD boosted by RTV 100mg QD (TELEX II). Presented at the 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, April 16-18, 2007. Abstract/poster 22.